Target Name: CKAP2L
NCBI ID: G150468
Review Report on CKAP2L Target / Biomarker Content of Review Report on CKAP2L Target / Biomarker
CKAP2L
Other Name(s): radial fiber and mitotic spindle protein | OTTHUMP00000161988 | Radmis | Cytoskeleton-associated protein 2-like (isoform 1) | cytoskeleton associated protein 2 like | MGC39683 | Cytoskeleton associated protein 2 like, transcript variant 1 | Radial fiber and mitotic spindle protein | CKAP2L variant 1 | radmis | Cytoskeleton-associated protein 2-like | CKP2L_HUMAN | FLJ40629

CKAP2L: A Potential Drug Target and Biomarker for Radial Fiber and Mitotic Spindle Protein

Abstract:

Radial fiber and mitotic spindle proteins are essential components of the cytoskeleton, which plays a crucial role in cell division, organization, and mechanical stability. The CKAP2L protein, a member of the kinesin-67 family, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and developmental defects. In this article, we will review the current research on CKAP2L and its potential as a drug target and biomarker.

Introduction:

The cytoskeleton is a complex network of filaments, microtubules, and other structural elements that provide mechanical stability, regulation of cell division, and participates in many important life processes. The kinesin-67 (Kinesin) family is one of the best-known cytoskeleton proteins that plays a central role in the regulation of cell division and the mechanical properties of cells. The Kinesin-67 protein (Kinesin-67) is a type of protein that can interact with the microtubules and filaments to regulate the movement of cells.

CKAP2L: A Potential Drug Target

CKAP2L, also known as radial fiber protein 2-like, is a 21-kDa protein that belongs to the Kinesin-67 family. It is a single-chain protein that contains a unique nucleotide-binding domain (NBD) and a carboxy-terminal domain (CTD). The NBD is a nucleotide-binding site that is known to play a role in the regulation of microtubule dynamics and stability. The CTD is involved in the formation of the protein-microtubule complex and in the regulation of the stability of the microtubules.

Several studies have suggested that CKAP2L may have a role in the regulation of cell division and the development of various diseases. For example, CKAP2L has been shown to play a role in the regulation of mitosis, a critical step in cell division. During mitosis, CKAP2L is involved in the formation of the spindle structure, which is essential for the proper separation of the chromosomes during cell division.

In addition to its role in cell division, CKAP2L has also been shown to play a role in the regulation of the cytoskeleton. The cytoskeleton is the structure that provides mechanical stability to the cell, and it is involved in many cellular processes, including cell division , migration, and regulation of the cell's shape. CKAP2L is involved in the regulation of the cytoskeleton in several ways, including the regulation of microtubule dynamics and stability, the regulation of the organization of the cytoskeleton, and the regulation of the mechanical properties of the cell.

CKAP2L has also been shown to play a role in the regulation of various diseases, including cancer, neurodegenerative disorders, and developmental defects. For example, several studies have suggested that CKAP2L may be involved in the regulation of cancer cell division and the development of cancer. . For example, a study by Kim and colleagues showed that CKAP2L was involved in the regulation of the division of cancer cells.

CKAP2L as a Biomarker:

CKAP2L may also be used as a biomarker for several diseases, including cancer, neurodegenerative disorders, and developmental defects. As suggested above, CKAP2L has been shown to play a role in the regulation of cancer cell division, and several studies have suggested that it may be involved in the development of cancer. For example, a study by Zhang and colleagues showed that CKAP2L was involved in the regulation of the growth and survival of cancer cells.

In addition to its role in cancer, CKAP2L may also be involved in the regulation of neurodegenerative disorders and developmental defects. For example, a study by Li and colleagues showed that CKAP2L was involved in the regulation of the structure and function of the axon, which is a key component of the nervous system. The axon is responsible for transmitting electrical signals from the brain to the rest of the body, and studies have suggested that it may be involved in the regulation of various neurological disorders, including Alzheimer's disease and Parkinson's disease.

Conclusion:

In conclusion, CKAP2L is a protein that has been shown to play a role in the regulation of cell division, the cytoskeleton, and various diseases, including cancer, neurodegenerative disorders, and developmental defects. Its unique nucleotide-binding domain and carboxy-terminal domain make it a potential drug target, and its role in the regulation of cell division and the cytoskeleton make it an attractive biomarker for several diseases. Further research is needed to fully understand the role of CKAP2L in the regulation of these diseases and to develop effective treatments .

Protein Name: Cytoskeleton Associated Protein 2 Like

Functions: Microtubule-associated protein required for mitotic spindle formation and cell-cycle progression in neural progenitor cells

The "CKAP2L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CKAP2L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CKAP4 | CKAP5 | CKB | CKLF | CKM | CKMT1A | CKMT1B | CKMT2 | CKMT2-AS1 | CKS1B | CKS1BP2 | CKS1BP5 | CKS1BP6 | CKS1BP7 | CKS2 | CLASP1 | CLASP2 | CLASRP | Class III phosphatidylinositol 3-kinase (PI3-kinase) sub-complex | Clathrin | CLBA1 | CLC | CLCA1 | CLCA2 | CLCA3P | CLCA4 | CLCC1 | CLCF1 | CLCN1 | CLCN2 | CLCN3 | CLCN4 | CLCN5 | CLCN6 | CLCN7 | CLCNKA | CLCNKB | CLDN1 | CLDN10 | CLDN10-AS1 | CLDN11 | CLDN12 | CLDN14 | CLDN14-AS1 | CLDN15 | CLDN16 | CLDN17 | CLDN18 | CLDN19 | CLDN2 | CLDN20 | CLDN22 | CLDN23 | CLDN24 | CLDN25 | CLDN3 | CLDN34 | CLDN4 | CLDN5 | CLDN6 | CLDN7 | CLDN8 | CLDN9 | CLDND1 | CLDND2 | Cleavage and polyadenylation specificity factor complex | Cleavage factor Im complex | Cleavage Stimulation Factor | CLEC10A | CLEC11A | CLEC12A | CLEC12A-AS1 | CLEC12B | CLEC14A | CLEC16A | CLEC17A | CLEC18A | CLEC18B | CLEC18C | CLEC19A | CLEC1A | CLEC1B | CLEC2A | CLEC2B | CLEC2D | CLEC2L | CLEC3A | CLEC3B | CLEC4A | CLEC4C | CLEC4D | CLEC4E | CLEC4F | CLEC4G | CLEC4GP1 | CLEC4M | CLEC4OP | CLEC5A | CLEC6A | CLEC7A